Eli Lilly UK is seeking a Director of Clinical Pharmacology and Translational Modeling to lead scientific strategies in the development of gene editing therapies for cardiovascular diseases. The ideal candidate will have extensive pharmaceutical or biotechnology experience and a strong background in clinical pharmacology and pharmacometrics
Job Summary
This role provides scientific leadership for clinical pharmacology and translational modeling across Verve's cardiovascular gene editing pipeline.
The position requires developing comprehensive strategies for preclinical-to-clinical translation, dose selection, and regulatory filing for lipid nanoparticle therapeutics.
Candidates will benefit from a comprehensive program including company bonuses, 401(k) matching, and extensive health and well-being benefits.
Matching Summary
Match Score: 85
Eli Lilly UK is seeking a Director of Clinical Pharmacology and Translational Modeling to lead scientific strategies in the development of gene editing therapies for cardiovascular diseases. The ideal candidate will have extensive pharmaceutical or biotechnology experience and a strong background in clinical pharmacology and pharmacometrics.
Salary
Base: $193,500 - $338,800; Bonus/Equity: Eligible for company bonus based on performance; Benefits: Comprehensive medical, dental, vision, 401(k), and wellness programs
Skills & Requirements
Must-have
PhD in Pharmaceutical Sciences or related field
10+ years clinical pharmacology experience
Population PK/PD modeling with NONMEM or Monolix
PBPK and QSP modeling expertise
Regulatory submission authoring for IND/NDA/BLA
Nice-to-have
Experience with LNP-delivered gene editing therapies
Proficiency in R programming for data analysis
Bayesian methods and optimal design knowledge
Track record of peer-reviewed publications
Cross-functional leadership in matrixed environments
Key Requirements
Ph.D. in Pharmaceutical Sciences, Pharmacology, or related quantitative field
Minimum 10+ years industry experience in clinical pharmacology
Proven track record of FDA/EMA regulatory interactions